SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (4350)7/25/2001 11:48:13 PM
From: Harold Engstrom  Respond to of 52153
 
Michael,

There has been excellent news flow about product development. s-zopiclone, s-oxybutynin, r,r-formoterol, Xopenex (ANDA), Soltara (NDA) and others have seen progress this year.

There will be significant developments, as outlined by the company, over the next two years.

H



To: Michael Young who wrote (4350)7/26/2001 10:33:07 AM
From: Biomaven  Read Replies (2) | Respond to of 52153
 
Michael,

I think a good case can be made that SEPR's current market cap is justified based on two existing drugs on the market (Allegra and Xopenex). That's why it remains by far my biggest holding.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News